CC
JUNO

Casdin Capital’s Juno Therapeutics, Inc. JUNO Stock Holding History

Casdin Capital’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-17,500
Closed -$769K – 37
2015
Q4 		$769K Buy
+17,500
New +$868K 0.68% 26

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BCM
Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Casdin Capital's JUNO Position: Q1 2016 in Review

Casdin Capital sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2016, closing a stake of 17,500 shares — an estimated $769K sold.

Casdin Capital first reported a position in JUNO in Q4 2015 and held it in 1 quarter. The position peaked at $769K in Q4 2015. 158 funds tracked by Wall St. Rank hold JUNO as of Q1 2016.

  • Casdin Capital reported no remaining Juno Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Casdin Capital sold 17,500 Juno Therapeutics, Inc. shares in Q1 2016, an estimated $769K.
  • Casdin Capital first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Casdin Capital's Juno Therapeutics, Inc. position peaked at $769K in Q4 2015.
  • 158 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2016.

Based on Casdin Capital's 13F filing for Q1 2016, filed 9 May 2016.